+
Site Tour
TRANSCATHETER
MITRAL AND TRICUSPID INTERVENTIONS
TRANSCATHETER
MITRAL AND TRICUSPID INTERVENTIONS

The most durable data.1

Anything less is just marketing.

KNOW THE DATA

MitraClip™ and TriClip™ TEER systems are engineered for long product life, with features that provide performance physicians and patients can truly count on. They’re engineered to deliver sustained MR and TR reduction and proven durable outcomes, with the compelling data to keep proving it. MitraClip and TriClip TEER systems are Engineered for Life.

Engineered to provide maximized durable regurgitation reduction

MITRACLIP™ TEER
MAXIMIZED MR REDUCTION UP TO 5 YEARS ACROSS MULTIPLE STUDIES

82%

of patients achieved MR ≤ 2+ at 5 years in EVEREST II RCT2

88%

of patients achieved MR ≤ 2+ at 5 years in REALISM HR3

95%

of patients achieved MR ≤ 2+ at 5 years in COAPT4

TRICLIP™ TEER
SIGNIFICANT, SUSTAINED TR REDUCTION

TRILUMINATE 3 YEARS

79%

of patients achieved TR grade < 2 at 3-years in TRILUMINATE 5

TRILUMINATE PIVOTAL 2 YEARS

84%

of patients achieved TR grade < 2 at 2 years in TRILUMINATE PIVOTAL 6

Engineered to deliver sustained annular reduction

The controlled and stable closing mechanism delivers sustained annular reduction.7-10

MITRACLIP™ TEER

AP REDUCTION

MITRAL DIAMETER*

¶ Statistically significant change from baseline, directly after clipping and 1 year follow-up for primary (pmr) and secondary (smr) AP-diameter changes
* Adapted from Schueler R, Kaplan S, Melzer C, et al. Impact of interventional edge-to-edge repair on mitral valve geometry. Int J Cardiol. 2017;230:468-475.

TRICLIP™ TEER

TRICUSPID DIAMETER*

A statistically significant change from baseline and 30 days in Septal-lateral diameter in the bRIGHT study; 4.34cm, 4.08cm and 4.03cm respectively.
* Adapted from table in Lurz P, Stephan von Bardeleben R, Weber M, et al. Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation.  J Am Coll Cardiol. 2021;77(3):229-239.

TRICUSPID ANNULAR REDUCTION SIMULATION

Engineered to establish long-term improvement in quality of life

MITRACLIP™ TEER

99%
FREEDOM FROM DEVICE-SPECIFIC COMPLICATIONS THROUGH FIVE YEARS3

47%
RELATIVE RISK REDUCTION IN HEART-FAILURE HOSPITALIZATION VERSUS SURGERY (EVEREST II RCT) OR VERSUS GDMT-ALONE (COAPT™ TRIAL)

99%
FREEDOM FROM DEVICE-SPECIFIC COMPLICATIONS THROUGH FIVE YEARS3

47%
RELATIVE RISK REDUCTION IN HEART-FAILURE HOSPITALIZATION VERSUS SURGERY (EVEREST II RCT) OR VERSUS GDMT-ALONE (COAPT™ TRIAL)

91%
OF PATIENTS IN NYHA FUNCTIONAL CLASS I/II AT 5 YEARS EVEREST II RCT (2007-2013 GEN1)2

72%
OF PATIENTS IN NYHA FUNCTIONALCLASS I/II AT 5 YEARS COAPT™ TRIAL (2012-2017 GEN1)4

91%
OF PATIENTS IN NYHA FUNCTIONAL CLASS I/II AT 5 YEARS EVEREST II RCT (2007-2013 GEN1)2

72%
OF PATIENTS IN NYHA FUNCTIONALCLASS I/II AT 5 YEARS COAPT™ TRIAL (2012-2017 GEN1)4

TRICLIP™ TEER

86%
REDUCTION IN HEART FAILURE HOSPITALIZATIONS AT 3 YEARS FROM BASELINE5

SIGNIFICANT
REDUCTIONS IN RVEDD AND TRICUSPID ANNULAR DIAMETER WERE DURABLE THROUGH 3 YEARS4

86%
REDUCTION IN HEART FAILURE HOSPITALIZATIONS AT 3 YEARS FROM BASELINE5

SIGNIFICANT
REDUCTIONS IN RVEDD AND TRICUSPID ANNULAR DIAMETER WERE DURABLE THROUGH 3 YEARS4

10 POINT
KCCQ-OS IMPROVEMENT OVER BASELINE IN 50% OF SUBJECTS AT 3 YEARS4

15 POINT
KCCQ-OS IMPROVEMENT AT 2 YEARS 5

10 POINT
KCCQ-OS IMPROVEMENT OVER BASELINE IN 50% OF SUBJECTS AT 3 YEARS4

15 POINT
KCCQ-OS IMPROVEMENT AT 2 YEARS 5


LET’S TALK ABOUT DURABILITY

SHARE YOUR MOST DURABLE TEER CASE

SUBMIT YOUR CASE

SAFETY IS A JOURNEY

MITRACLIP" AND TRICLIP" THERAPIES DESIGNED FOR YOU TO BE IN CONTROL
 

MORPHOLOGY OF THE MITRAL AND
TRICUSPID VALVES
Pr. A. COOK

Discover why Experience Matters

WATCH HOW MITRACLIP™ TEER TRANSFORMED LUCA'S LIFE

WATCH HOW TRICLIP™ TEER TRANSFORMED CRUZ'S LIFE

References
  1. Stone et al., 2023 NEJM COAPT 5-Year Outcome. Feldman et al., 2015 JACC 5 Yr EVEREST II RCT. Nickenig et al., 2024 JACC 3-Year Outcomes from the TRILUMINATE Study.
  2. Feldman T, et al. Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. J Am Coll Cardiol. 2015 Dec 29;66(25):2844-2854
  3. EVEREST II REALISM Continued Access Study High Risk Group. Final Report Feb 2018. Data on File at Abbott.
  4. Stone G, et al. Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation, N Engl J Med 2023; 388;2037-2048
  5. Nickenig G et al. 2024 JACC 3-Year Outcomes from the TRILUMINATE Study
  6. Kar S. Two-Year Outcomes of Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation: The Triluminate Pivotal Trial. Presented at ACC; March 30, 2025; Chicago, U.S.
  7. Schueler R, Kaplan S, Melzer C, et al. Impact of interventional edge-to-edge repair on mitral valve geometry. Int J Cardiol. 2017;230:468-475.
  8. Herbrand T, Eschenhagen S, Zeus T, et al. Acute reverse annular remodeling during MitraClip® therapy predicts improved clinical outcome in heart failure patients: a 3D echocardiography study. Eur J Med Res. 2017;22(1):33. Published 2017 Sep 20.
  9. Mack MJ, et al. 3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. J Am Coll Cardiol. 2021;77(8):1029-1040.
  10. Lurz P, Stephan von Bardeleben R, Weber M, et al. Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation. J Am Coll Cardiol.2021;77(3):229-239.

© Abbott 2025. All rights reserved. 9-EH-5-15223-01 04-2025 REV B

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline